Clinical trials: Hydroxychloroquine
Breast Cancer
Autophagy Inhibition Using Hydrochloroquine in Breast Cancer Patients
Hydroxychloroquine is a drug that has been used to treat malaria and rheumatism. It is recently discovered that Hydroxychloroquine increases 'autophagy'.
- Trial name
- NCT01292408
- Testing
- Hydrochloroquine
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- Radboud University Medical Center
COVID-19
Hydroxychloroquine and Zinc With Either Azithromycin or Doxycycline for Treatment of COVID-19 in Outpatient Setting
This is a randomized, open-label trial to assess the safety and efficacy of hydroxychloroquine, and zinc in combination with either azithromycin or doxycycline in a higher risk COVID-19 positive outpatient population.
- Trial name
- NCT04370782
- Testing
- Hydroxychloroquine, Azithromycin, Zinc Sulfate
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- St. Francis Hospital, New York
Tumor, Solid, Gastrointestinal Cancer
Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies
This is an open-label, prospective phase two basket trial assessing the efficacy of ulixertinib in combination with hydroxychloroquine in patients with advanced gastrointestinal malignancies.
- Trial name
- NCT05221320
- Testing
- Ulixertinib, Hydroxychloroquine
- Where
- 9 sites in United States
- Volunteers
- 47 people
- Sponsor
- BioMed Valley Discoveries, Inc
COVID-19
Hydroxychloroquine Use in Hospitalized Patients With COVID-19: Impact on Progression to Severe or Critical Disease
The primary objective is to assess the impact of hydroxychloroquine in hospitalized patients with COVID-19 and risk factors for severe/critical disease.
- Trial name
- NCT04429867
- Testing
- Hydroxychloroquine
- Where
- United States
- Volunteers
- 700 people
- Sponsor
- WellStar Health System
Myelodysplastic Syndromes, Progressive Disease
CPI-613 and Hydroxychloroquine for Patients With High Risk Myelodysplastic Syndrome
This is a phase 1/2 study of the combination of CPI-613 and hydroxychloroquine for the treatment of high risk myelodysplastic syndrome patients who have failed a hypomethylating agent.
- Trial name
- NCT03929211
- Testing
- CPI-613, Hydroxychloroquine
- Where
- 2 sites in United States
- Sponsor
- Wake Forest University Health Sciences
Insulin Resistance
Rediscovering Hydroxychloroquine as a Novel Insulin Sensitizer
Current options to treat insulin resistance in diabetes are fairly limited. For this reason, novel treatments would represent a major progress.
- Trial name
- REHNIS (NCT02124681)
- Testing
- Hydroxychloroquine
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Hydroxychloroquine, Gemcitabine
Hydroxychloroquine Combined With Gemcitabine in the Treatment of Advanced Non-small Cell Lung Cancer
To evaluate the efficacy and safety of hydroxychloroquine (600mgBID) combined with gemcitabine (1000mg/m2,d1,8) in the third-line and above treatment of advanced NSCLC.
- Conditions
- Hydroxychloroquine, Gemcitabine, Lung Neoplasms
- Trial name
- NCT05647330
- Testing
- Hydroxychloroquine Combined With Gemcitabine
- Volunteers
- 55 people
- Sponsor
- Henan Cancer Hospital
Rheumatoid Arthritis, Insufficient Response to Methotrexate or Leflunomide
Clinical Trial Evaluating Methotrexate or Leflunomide + Targeted Therapy Versus Methotrexate or Leflunomide + Sulfasalazine + Hydroxychloroquine in Patients With Rheumatoid Arthritis and Insufficient Response to Methotrexate or Leflunomide
Approximately, 40 to 50% of patients with rheumatoid arthritis (RA), the most frequent inflammatory arthritide, are non responders to the consensual 1st line of treatment : methotrexate.
- Trial name
- BIO3 (NCT02714634)
- Testing
- Methotrexate + targeted therapy administration, methotrexate or leflunomide + sulfasalazine + hydroxychloroquine administration
- Where
- France
- Volunteers
- 286 people
- Sponsor
- University Hospital, Strasbourg, France
Hepatocellular Cancer
Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer
The PI is studying if sorafenib/hydroxychloroquine (HCQ) will have improved efficacy when compared to sorafenib alone and in patients progressing of sorafenib the addition of HCQ would lead to disease stability in patients with…
- Trial name
- NCT03037437
- Testing
- Sorafenib (SOR), Hydroxychloroquine (HCQ)
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Preeclampsia
Hydroxychloroquine in Prevention of Preeclampsia
Pre-eclampsia complicates up to 8% of pregnancies and is a major contributor to maternal mortality and morbidity The only effective treatment is delivery, which leads to significant neonatal morbidity and mortality if carried out…
- Trial name
- NCT04755322
- Testing
- Hydroxychloroquine, Folic acid, Low-dose aspirin
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Assiut University
COVID-19
Hydroxychloroquine and Ivermectin for the Treatment of COVID-19 Infection
Background: In December 2019, patients with pneumonia secondary to a new subtype of Coronavirus (COVID-19) were identified in China. In a few weeks the virus spread and cases started practically all over the world.
- Trial name
- NCT04391127
- Testing
- Hydroxychloroquine, Ivermectin
- Where
- Mexico
- Volunteers
- 108 people
- Sponsor
- Centenario Hospital Miguel Hidalgo
COVID-19
Safety and Efficacy of Doxycycline and Rivaroxaban in COVID-19
This is an exploratory study to evaluate the efficacy of Doxycycline (200mg on D1 to D7) and Rivaroxaban (15 mg daily on D1 to D7) versus the combination of Hydroxychloroquine (400 mg on D1 to D7) and Azithromycin (500 mg on D1…
- Trial name
- DOXYCOV (NCT04715295)
- Testing
- Doxycycline Tablets, Rivaroxaban 15Mg Tab, Hydroxychloroquine and Azithromycin
- Where
- Cameroon
- Volunteers
- 200 people
- Sponsor
- Yaounde Central Hospital
COVID-19
Non-comparative Trial of the Combination of HCQ and AZI in the Treatment of ICU Patients
This research is designed as an open-label,non-comparative prospective trial.
- Trial name
- NCT04458948
- Testing
- Hydroxychloroquine, Azithromycin
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of New Mexico
COVID-19
Randomized Placebo-controlled Trial of Hydroxychloroquine in Outpatient Cases With Coronavirus Disease 2019 (COVID-19)
In December 2019, a group of patients with pneumonia of unknown cause was identified in Wuhan, in the Hubei province, China. Despite the need of target specific therapeutic options for COVID-19, until now there is no proof of…
- Trial name
- COALITION-V (NCT04466540)
- Testing
- Hydroxychloroquine
- Where
- 69 sites in Brazil
- Volunteers
- 1,372 people
- Sponsor
- Hospital Alemão Oswaldo Cruz
COVID-19
Hydroxychloroquine and Azithromycin as Prophylaxis for Healthcare Workers Dealing With COVID19 Patients
The main objective of this study is to assess the efficacy of the combination hydroxychloroquine and Azithromycin (HCQ and AZ) in reducing the infection risk among health care professionals in direct contact with COVID-19…
- Trial name
- MOPHYDA (NCT04354597)
- Testing
- HCQ & AZ
- Where
- Jordan
- Volunteers
- healthy volunteers welcome
- Sponsor
- King Hussein Cancer Center
Systemic Lupus, Skin Lupus
Lupus and Observance
A poor therapeutic observance is described between 3 and 76% cases in systemic lupus. It is associated with an increased risk of relapses, hospitalizations, morbidity and poor renal prognosis.
- Trial name
- LUPOBS (NCT03019926)
- Testing
- Hydroxychloroquine dosage
- Where
- France
- Volunteers
- 200 people
- Sponsor
- University Hospital Center of Martinique
Recurrent Pregnancy Loss, Euthyroid With Thyroid Antibodies
Effect of HCQ Combined With LT4 on LBR in Euthyroid Women With URPL and TPO-Ab
The goal of this clinical trial is to learn if combined treatment of levothyroxine and hydroxychloroquine would improve the live birth of euthyroid women with thyroid peroxidase antibodies and unexplained recurrent pregnancy…
- Trial name
- QT-LIFE (NCT06652113)
- Testing
- hydroxychloroquine and levothyroxine, Levothyroxine
- Where
- 2 sites in China
- Volunteers
- 796 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Metastatic Pancreatic Carcinoma, Stage II Pancreatic Cancer
Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer
This phase I trial studies the sides effects and best dose of hydroxychloroquine when given together with trametinib in treating patients with pancreatic cancer that has spread to nearby tissue, lymph nodes or other places in the…
- Conditions
- Metastatic Pancreatic Carcinoma, Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer
- Trial name
- THREAD (NCT03825289)
- Testing
- Hydroxychloroquine, Trametinib
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- University of Utah